Pharma Equity Group A/S (CPH:PEG)

Market Cap	120.30M -41.1%
Revenue (ttm)	n/a
Net Income	-21.02M
EPS	-0.02
Shares Out	1.23B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	800,612
Average Volume	205,135
Open	0.1125
Previous Close	0.1125
Day's Range	0.0970 - 0.1125
52-Week Range	0.0706 - 0.1545
Beta	1.01
RSI	43.49
Earnings Date	Mar 18, 2026

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of Ulcus Cruris chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Denmark
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG